US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Exact gatecrashes the liquid biopsy party
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The Thermo-Qiagen saga comes to an end
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Few groups have developed Covid-19 diagnostics – but this will change
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
